• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET

    5/6/24 4:01:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENTA alert in real time by email
    • Anticipates Reporting Topline Data from EDP-323 Respiratory Syncytial Virus (RSV) Challenge Study in Q3 2024 and Phase 2 Study of Zelicapavir in Pediatric RSV Patients in 2H 2024
    • Selection of Chronic Spontaneous Urticaria (CSU) Development Candidate Targeted for Q4 2024
    • Operations Supported by Cash and Marketable Securities Totaling $300.3 Million at March 31, 2024, as well as Continuing Retained Royalties

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal second quarter ended March 31, 2024.

    "At Enanta, we are committed to advancing the first antiviral treatment for RSV, and more broadly developing important medicines in virology and immunology. Our commitment is highlighted by our goal to deliver multiple RSV data readouts this year, including from our challenge study of EDP-323, an oral L-protein inhibitor, expected in the third quarter, and from RSVPEDs, our Phase 2 pediatric study of zelicapavir, an oral N-protein inhibitor. In RSVPEDs, we are nearing study completion and are now only enrolling patients aged 28 days to 6 months, which is the last age cohort in Part 2. As this narrows the eligible patient population, we will continue recruiting in the Southern Hemisphere and anticipate reporting data from this study in the second half of 2024," said Jay R. Luly, Ph.D., President and Chief Executive Officer at Enanta Pharmaceuticals. "Pending positive data from these studies, we will be poised to deliver potential first-in-class antiviral replication inhibitors with differentiated mechanisms of action and advance our robust RSV portfolio. Beyond RSV, we are eager to help patients affected by CSU, a severely debilitating inflammatory skin disease, with our first immunology program focused on developing oral KIT inhibitors. We are on track to select a KIT inhibitor development candidate in the fourth quarter and look forward to expanding more broadly into immune-mediated chronic diseases with a second program this year."

    Fiscal Second Quarter Ended March 31, 2024 Financial Results

    Total revenue for the three months ended March 31, 2024 was $17.1 million and consisted of royalty revenue from worldwide net sales of AbbVie's hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir), compared to $17.8 million for the three months ended March 31, 2023.

    A portion (54.5%) of Enanta's ongoing royalty revenue from AbbVie's net sales of MAVYRET®/MAVIRET® is paid to OMERS, one of Canada's largest defined benefit pension plans, pursuant to a royalty sale transaction affecting royalties earned after June 2023. For financial reporting purposes, the transaction was treated as debt, with the upfront purchase payment of $200.0 million recorded as a liability. Each quarter, Enanta records 100% of the royalty earned as revenue and then amortizes the debt liability proportionally as 54.5% of the cash royalty payments are paid to OMERS through June 30, 2032 subject to a cap of 1.42 times the purchase payment, after which point 100% of the cash royalty payments will be retained by Enanta. Interest expense from the royalty sale was $2.6 million for the three months ended March 31, 2024.

    Research and development expenses totaled $35.6 million for the three months ended March 31, 2024, compared to $43.5 million for the three months ended March 31, 2023. The decrease was primarily due to a decrease in costs associated with Enanta's COVID-19 program, as the company announced previously that plans to pursue any future COVID-19 efforts would be in the context of a collaboration. This decrease was partially offset by increased costs associated with Enanta's RSV programs and its recently announced immunology programs.

    General and administrative expenses totaled $14.2 million for the three months ended March 31, 2024, compared to $13.8 million for the three months ended March 31, 2023. The increase was primarily due to an increase in legal expenses related to the company's patent infringement lawsuit against Pfizer.

    Enanta recorded an income tax benefit of $0.4 million for the three months ended March 31, 2024, for interest earned on a pending $28.0 million federal income tax refund, compared to an income tax expense of less than $0.1 million for the three months ended March 31, 2023.

    Net loss for the three months ended March 31, 2024 was $31.2 million, or a loss of $1.47 per diluted common share, compared to a net loss of $37.7 million, or a loss of $1.79 per diluted common share, for the corresponding period in 2023.

    Enanta is updating its expense guidance at this fiscal year mid-point. Research and development expense is $125 million to $145 million. General and administrative expense is $50 million to $60 million. The research and development expense increase reflects the impact of the company's new immunology programs as well as additional efforts to accelerate the RSV clinical studies. The general and administrative expense increase is due to additional stock compensation expense and costs associated with pursuing the company's patent infringement lawsuit.

    Enanta's cash, cash equivalents and short-term marketable securities totaled $300.3 million at March 31, 2024. Enanta expects that its current cash, cash equivalents and marketable securities, as well as its retained portion of future royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs through the third quarter of fiscal 2027.

    Virology

    RSV

    • Enanta is advancing multiple clinical programs through a robust antiviral treatment portfolio aimed at populations at high-risk for serious outcomes from RSV infection. This includes zelicapavir, Enanta's lead, oral N-protein inhibitor, and EDP-323, its oral L-protein inhibitor.
      • Zelicapavir is being evaluated in two ongoing Phase 2 clinical trials in high-risk pediatric and adult populations.
        • RSVPEDs is a first-in-pediatrics Phase 2, randomized, double-blind, placebo-controlled study of zelicapavir in hospitalized and non-hospitalized RSV patients that are 28 days to three years of age. The study is near completion and has fully enrolled Part 1, and the older age cohort of Part 2. The remaining younger age cohort of 20 patients in Part 2 is partially enrolled. Recruitment for this cohort will continue in the Southern Hemisphere and Enanta now anticipates reporting data from this study in the second half of 2024.
        • RSVHR is a Phase 2b, randomized, double-blind, placebo-controlled study of zelicapavir in adults with RSV infection who are at high risk of complications, including the elderly and/or those with congestive heart failure, chronic obstructive pulmonary disease or asthma. Enrollment in RSVHR is progressing and the company will provide additional guidance on the study as the Southern Hemisphere RSV season advances.
      • Enanta's second RSV program, EDP-323, is on track to announce data from its Phase 2a challenge study in the third quarter of 2024. This randomized, double-blind, placebo-controlled, human challenge study will evaluate the safety, pharmacokinetics, and changes in viral load measurements and symptoms in up to 114 healthy adult subjects who will be infected with RSV.

    Immunology

    • Enanta continues to progress its initial immunology program aimed at developing KIT inhibitors to treat CSU, a highly debilitating inflammatory skin disease characterized by recurrent hives that can last for years. CSU is estimated to affect up to 1% of the global population and represents a large market opportunity, as currently there are limited effective oral treatment options for the condition. Enanta's goal is to address the significant unmet need in CSU treatment by developing a best-in-disease, oral KIT inhibitor therapy that targets mast cells, which play a crucial role in the disease. As mast cells are involved in other allergic diseases, this approach may be leveraged for future programs in other immunology indications.
      • Preclinical optimization of Enanta's potent and selective oral KIT inhibitors for CSU is ongoing. The company anticipates selecting a CSU development candidate in the fourth quarter of 2024 and plans to move into the clinic shortly thereafter.
    • Enanta plans to expand its presence in immunology and introduce a second program in 2024.

    Corporate

    • In April, Enanta announced the appointment of Matthew P. Kowalsky, J.D., as its Chief Legal Officer. Mr. Kowalsky brings more than 20 years of experience in the life sciences industry handling legal matters across a range of disciplines, including corporate governance, public company reporting, intellectual property, financing, business development and M&A activities. As Enanta's Chief Legal Officer, he will lead all legal and compliance activities for the company and provide strategic guidance and corporate governance oversight. Prior to joining Enanta, Mr. Kowalsky held legal and operational roles of increasing responsibility at Sigilon Therapeutics, Inc., until its acquisition by Eli Lilly.

    Upcoming Events and Presentations

    • JMP Securities Life Sciences Conference, May 14, 2024
    • Jefferies Healthcare Conference, June 5, 2024
    • Enanta plans to issue its fiscal third quarter financial results press release on August 5, 2024.

    Conference Call and Webcast Information

    Enanta will host a conference call and webcast today at 4:30 p.m. ET. The live webcast can be accessed at "Events & Presentations" in the investors section of Enanta's website. To participate by phone, please register for the call here. It is recommended that participants register a minimum of 15 minutes before the call. Once registered, participants will receive an email with the dial-in information. The archived webcast will be available on Enanta's website for approximately 30 days following the event.

    About Enanta Pharmaceuticals, Inc.

    Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.

    Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit www.enanta.com for more information.

    Forward Looking Statements

    This press release contains forward-looking statements, including statements with respect to the prospects for advancement of Enanta's clinical programs in RSV and its preclinical program in CSU. Statements that are not historical facts are based on management's current expectations, estimates, forecasts and projections about Enanta's business and the industry in which it operates and management's beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the impact of development, regulatory and marketing efforts of others with respect to vaccines and competitive treatments for RSV and CSU; the discovery and development risks of Enanta's programs in virology and immunology; Enanta's lack of clinical development experience; Enanta's need to attract and retain senior management and key research and development personnel; Enanta's need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in "Risk Factors" in Enanta's Form 10-K for the fiscal year ended September 30, 2023, and any other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.

    Tables to Follow

     

    ENANTA PHARMACEUTICALS, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    UNAUDITED

    (in thousands, except per share amounts)

     

    Three Months Ended

     

    Six Months Ended

    March 31,

     

    March 31,

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

     
    Revenue

    $

    17,054

     

    $

    17,795

     

    $

    35,057

     

    $

    41,380

     

    Operating expenses
    Research and development

     

    35,585

     

     

    43,468

     

     

    71,956

     

     

    84,370

     

    General and administrative

     

    14,235

     

     

    13,778

     

     

    30,753

     

     

    26,474

     

    Total operating expenses

     

    49,820

     

     

    57,246

     

     

    102,709

     

     

    110,844

     

    Loss from operations

     

    (32,766

    )

     

    (39,451

    )

     

    (67,652

    )

     

    (69,464

    )

    Interest expense

     

    (2,563

    )

     

    —

     

     

    (6,004

    )

     

    —

     

    Interest and investment income, net

     

    3,809

     

     

    1,837

     

     

    8,107

     

     

    2,830

     

    Loss before income taxes

     

    (31,520

    )

     

    (37,614

    )

     

    (65,549

    )

     

    (66,634

    )

    Income tax benefit (expense)

     

    363

     

     

    (44

    )

     

    985

     

     

    (10

    )

    Net loss

    $

    (31,157

    )

    $

    (37,658

    )

    $

    (64,564

    )

    $

    (66,644

    )

    Net loss per share
    Basic

    $

    (1.47

    )

    $

    (1.79

    )

    $

    (3.06

    )

    $

    (3.19

    )

    Diluted

    $

    (1.47

    )

    $

    (1.79

    )

    $

    (3.06

    )

    $

    (3.19

    )

    Weighted average common shares outstanding
    Basic

     

    21,167

     

     

    21,035

     

     

    21,128

     

     

    20,882

     

    Diluted

     

    21,167

     

     

    21,035

     

     

    21,128

     

     

    20,882

     

    CONDENSED CONSOLIDATED BALANCE SHEETS

    UNAUDITED

    (in thousands)

     

    March 31,

     

    September 30,

     

    2024

     

     

     

    2023

    Assets
    Current assets
    Cash and cash equivalents

    $

    63,542

    $

    85,388

    Short-term marketable securities

     

    236,768

     

    284,522

    Accounts receivable

     

    7,756

     

    8,614

    Prepaid expenses and other current assets

     

    10,932

     

    13,263

    Income tax receivable

     

    32,031

     

    31,004

    Total current assets

     

    351,029

     

    422,791

    Property and equipment, net

     

    15,479

     

    11,919

    Operating lease, right-of-use assets

     

    42,894

     

    22,794

    Restricted cash

     

    3,968

     

    3,968

    Other long-term assets

     

    187

     

    803

    Total assets

    $

    413,557

    $

    462,275

    Liabilities and Stockholders' Equity
    Current liabilities
    Accounts payable

    $

    6,726

    $

    4,097

    Accrued expenses and other current liabilities

     

    10,630

     

    18,339

    Liability related to the sale of future royalties

     

    33,671

     

    35,076

    Operating lease liabilities

     

    3,581

     

    5,275

    Total current liabilities

     

    54,608

     

    62,787

    Liability related to the sale of future royalties, net of current portion

     

    147,776

     

    159,429

    Operating lease liabilities, net of current portion

     

    43,412

     

    21,238

    Series 1 nonconvertible preferred stock

     

    1,423

     

    1,423

    Other long-term liabilities

     

    224

     

    663

    Total liabilities

     

    247,443

     

    245,540

    Total stockholders' equity

     

    166,114

     

    216,735

    Total liabilities and stockholders' equity

    $

    413,557

    $

    462,275

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240506982878/en/

    Get the next $ENTA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ENTA

    DatePrice TargetRatingAnalyst
    8/9/2023$14.00Neutral → Underweight
    JP Morgan
    8/8/2023$49.00 → $18.00Buy → Hold
    Jefferies
    12/9/2022$56.00Buy
    H.C. Wainwright
    7/6/2022$62.00In-line → Outperform
    Evercore ISI
    6/1/2022$39.00Underperform → In-line
    Evercore ISI
    2/9/2022$80.00 → $68.00Market Perform
    SVB Leerink
    1/13/2022$85.00 → $80.00Market Perform
    SVB Leerink
    11/24/2021$55.00 → $73.00Perform
    Oppenheimer
    More analyst ratings

    $ENTA
    SEC Filings

    See more
    • SEC Form S-8 filed by Enanta Pharmaceuticals Inc.

      S-8 - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

      5/14/25 4:41:15 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Enanta Pharmaceuticals Inc.

      10-Q - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

      5/14/25 4:00:25 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

      5/12/25 4:05:15 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Enanta Pharmaceuticals downgraded by JP Morgan with a new price target

      JP Morgan downgraded Enanta Pharmaceuticals from Neutral to Underweight and set a new price target of $14.00

      8/9/23 7:32:28 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals downgraded by Jefferies with a new price target

      Jefferies downgraded Enanta Pharmaceuticals from Buy to Hold and set a new price target of $18.00 from $49.00 previously

      8/8/23 6:35:35 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Enanta Pharmaceuticals with a new price target

      H.C. Wainwright initiated coverage of Enanta Pharmaceuticals with a rating of Buy and set a new price target of $56.00

      12/9/22 7:40:58 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

      Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430622885/en/Matthew P. Kowalsky, Chief Legal Officer, Enanta Pharmaceuticals, Inc. (Photo: Business Wire) "I'm pleased to welcome Matt to Enanta. The breadth of his legal expertise ac

      4/30/24 7:00:00 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer

      Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022. With over 20 years of experience in drug development across a broad range of therapeutic areas, Dr. Rottinghaus will lead the development, regulatory, clinical and medical functions in support of Enanta's pipeline. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005491/en/Scott T. Rottinghaus, M.D., Senior Vi

      8/8/22 4:00:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development

      WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Brendan Luu as Senior Vice President, Business Development and member of the company’s senior management team. Mr. Luu brings more than 20 years of diversified business development and sales and marketing experience in the pharmaceutical and technology fields to Enanta, spanning a broad range of therapeutic areas, asset stages and deal structures. “It is an ideal time to welcome Brendan to the Enanta team, particularly as we prepare for a catalys

      1/26/21 7:00:00 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Financials

    Live finance-specific insights

    See more
    • Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

      Met Target Enrollment for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV); On Track to Report Topline Data in Late 3Q 2025 STAT6 Program Progressing with Plans to Select a Development Candidate in 2H 2025 IND Enabling Studies of KIT Inhibitor EPS-1421 Ongoing Cash and Marketable Securities Totaling $193.4 Million at March 31, 2025, Further Strengthened by a $33.8 Million Federal Income Tax Refund Received in April 2025 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results f

      5/12/25 4:01:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

      On Track to Report Topline Results for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in 3Q 2025 Advancing Immunology Portfolio with Ongoing IND Enabling Studies of KIT Inhibitor EPS-1421 On Track to Announce STAT6 Development Candidate in 2H 2025 Operations Supported by Cash and Marketable Securities Totaling $216.7 Million at December 31, 2024, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended D

      2/10/25 4:01:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

      Observed an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2 Demonstrated a viral load decline of 1.2 log compared to placebo at the end of treatment in prespecified analysis of patients randomized within 3 days of symptom onset Zelicapavir was well-tolerated with a favorable safety profile Conference call and webcast to discuss data at 8:30 a.m. ET today Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced positive topline results from

      12/9/24 6:30:00 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc.

      SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

      11/14/24 4:03:02 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc.

      SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

      10/17/24 4:31:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

      2/14/24 2:26:49 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Luly Jay R. bought $256,050 worth of shares (45,000 units at $5.69), increasing direct ownership by 6% to 846,638 units (SEC Form 4)

      4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

      2/12/25 8:09:35 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Vance Terry

      4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

      3/14/25 5:44:01 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Russell Lesley

      4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

      3/14/25 5:43:30 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Peterson Kristine

      4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

      3/14/25 5:43:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

      MAVYRET® (glecaprevir/pibrentasvir) is Now the Only Direct Acting Antiviral Therapy Approved to Treat Patients with Acute Hepatitis C Virus (HCV) in Eight Weeks with a 96% Cure Rate1*† FDA Approval Now Allows Providers to Treat HCV Patients Immediately at Time of Diagnosis If Left Untreated, Patients with Acute HCV Could Progress to Chronic Disease, Including Cirrhosis or Liver Cancer2 Glecaprevir, One of the Two Direct-Acting Antivirals in MAVYRET®, was Discovered by Enanta and Developed and Commercialized by AbbVie Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunologica

      6/11/25 12:34:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

      Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 8:10 a.m. ET in New York, NY. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days. About Enanta Pharmaceuticals

      5/27/25 7:00:00 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

      Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company's Phase 2 study of zelicapavir in young children infected with respiratory syncytial virus (RSV) will be available as an E-Poster at the 43rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2025, being held May 26-30, 2025 at the Bucharest International Conference Centre in Bucharest, Romania and online. The E-Poster will highlight results from a Phase 2 study of zelicapavir, an oral, non-nucleoside small-molecule RSV-replication-inhibitor (N

      5/22/25 7:00:00 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care